Loading current stock analysis…
Loading current stock analysis…
India
Reported ownership for FY2027-Q1 as of 2026-06-30.
As of 19 Oct 2026, 03:30 pm
Recent drawdown or price variability is high enough to warrant closer monitoring.
Primary driver: Price remains materially below a previous peak
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹7,043.50 crore | ₹6,605.50 crore | ₹6,477.40 crore | ₹6,303.50 crore | ₹5,842.10 crore |
| Finance Costs | PEAK₹120.40 crore | ₹119.10 crore | ₹112.60 crore | ₹109.60 crore | ₹108.30 crore |
| Other Expenses | PEAK₹1,558.50 crore | ₹1,420.50 crore | ₹1,380.70 crore | ₹1,352.10 crore | ₹1,230 crore |
| Profit Before Tax | PEAK₹785.40 crore | ₹711.40 crore | ₹667.10 crore | ₹668.40 crore | ₹569.10 crore |
| Tax Expense | PEAK₹188.40 crore | ₹170.20 crore | ₹165.70 crore | ₹180.70 crore | ₹141.70 crore |
| Profit Loss For Period | PEAK₹610.40 crore | ₹551.30 crore | ₹516.30 crore | ₹494 crore | ₹441 crore |
Revenue from operations reached ₹7,043.5 crore in Q1 FY2026-27, up from ₹5,842.1 crore a year ago. This 20.6% year-on-year growth follows a consistent upward trajectory: each of the previous four quarters has been higher than the one before. Sequentially, revenue grew 6.6% from ₹6,605.5 crore in Q4 FY2025-26, a faster pace than the 2.0% and 2.8% sequential gains in the two preceding quarters.
Other expenses increased 26.7% year-on-year to ₹1,558.5 crore, outpacing revenue growth by roughly 6 percentage points. Finance costs rose 11.2% to ₹120.4 crore, a slower increase. The effective tax rate declined slightly from 24.9% to 24.0%, adding to net profit growth.
Employee benefit expense was ₹795.8 crore and cost of materials consumed was ₹829 crore.
Segment revenue (which matches consolidated revenue) grew 20.6% year-on-year. Segment profit before tax rose 37.1% to ₹798.8 crore, compared with a 38.0% increase in consolidated PBT. The difference between segment PBT and consolidated PBT was ₹13.4 crore, virtually unchanged from ₹13.6 crore a year ago.
Segment PBT margin improved from 9.97% to 11.34%, a gain of 1.37 percentage points, broadly in line with the consolidated margin improvement.
Paid-up equity share capital remained unchanged at ₹71.9 crore.
Revenue grew 20.6% year-on-year to ₹7,043.5 crore, while profit before tax rose 38.0% to ₹785.4 crore. Net profit margin expanded by 1.12 percentage points to 8.67%. The margin improvement occurred even as other expenses increased 26.7%, outpacing revenue growth. Segment profit before tax grew 37.1%, with segment PBT margin rising 1.37 percentage points, consistent with the consolidated trend.
Disclosed bulk and block transactions involving Apollo Hospitals Enterprise, shown for the latest 90 days.
Exchange disclosures and regulatory announcements for Apollo Hospitals Enterprise.
Apollo Hospitals Enterprise Limited disclosed its schedule of analyst/institutional investor meetings: BOFA Securities I 2026 India Corporate Day on 17 November 2026 in Singapore, and Morgan Stanley’s Twenty-Fifth Annual Asia Pacific Summit on 18–19 November 2026 in Singapore. Both are listed as physical meetings with one-on-one and group sessions. The schedule is subject to change; the company stated that no unpublished price-sensitive information will be shared. This is a routine investor-meeting notice, not a substantive business announcement.
Apollo Hospitals Enterprise Limited has scheduled a conference call for analysts and institutional investors on Thursday, November 5, 2026, at 3:00 PM IST to discuss unaudited financial results for the three and six months ended September 30, 2026. The company will announce these financial results on Wednesday, November 4, 2026. The call will feature senior leadership including Managing Director Mrs. Suneeta Reddy, Group CFO Mr. A. Krishnan, and other key executives from Apollo HealthCo Ltd. and the Pharmacy business.
APOLLO HOSPITALS ENTERPRISE LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
Financial Results/Other business matters |Meeting Date: 04-Nov-2026
APOLLO HOSPITALS ENTERPRISE LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . |SUBJECT: Board Meeting Intimation
Board Meeting Intimation |Meeting Date: 04-Nov-2026
Apollo Hospitals Enterprise Limited has informed the Exchange regarding 'Certificate under Regulation 74(5) for the period ended 30th September 2026'. |SUBJECT: Updates
Apollo Hospitals Enterprise Limited will close its trading window for directors, designated employees, and insiders from Thursday, October 1, 2026, until 48 hours after the announcement of unaudited financial results for the three and six months ending September 30, 2026. This closure is mandated under SEBI (Prohibition of Insider Trading) Regulations, 2015, to prevent transactions in company securities during the consideration of these results. The intimation was issued on September 24, 2026, by Sankaran Arayana N Muthu Krishnan.
Recent market and company developments associated with Apollo Hospitals Enterprise.
The Supreme Court asked the government as to why can they not control the entire market of drugs and that they are only looking to strengthen the hands of the government.
Markets snap eight-week fall as Nifty, Sensex rise; financials lead gains while healthcare and IT drag amid RBI visit, global cues.
Hospital stocks extended losses for a second session after the Supreme Court questioned steep markups on cancer drugs and raised concerns over hospitals requiring patients to buy medicines from their own or designated pharmacies.
Hospital stocks, Hospital stocks news, Fortis Healthcare share price, Max share porice, Apollo Hospitals share rpice, Medanta share price, Manipal Health share price
Jefferies has maintained a Buy rating on six hospital stocks, including Apollo Hospitals and Fortis Healthcare, following a sharp correction driven by regulatory concerns over drug and consumable price caps. The brokerage expects strong fundamentals and strategic price adjustments to help limit long-term EBITDA impact.
hospital stocks today, healthcare stocks update, nifty healthcare update, apollo hospitals shares fall, max healthcare shares crash
Sensex Today | Nifty 50 | Stock Market Live Updates: Benchmark indices pared gains from the day’s highs and ended near the day’s lows amid heightened volatility at the start of the new series. Persistent global uncertainty and an intraday spike in Brent crude oil prices kept investors cautious.
The Supreme Court, on Tuesday, September 29, flagged how drugs cost 2,700 to a retailer and are billed at 27,000 to patients in hospitals. The top court questioned where the 10x markup on prices was going.
Comprehensive Section Breakdown for Apollo Hospitals Enterprise
Strategic Vision: Integrated healthcare provider operating hospitals, clinics, and pharmacies.
• Integrated network of physical and digital healthcare services.
• Wholesale pharmaceutical procurement and distribution capabilities.
• Referral network from primary care to tertiary hospitals.
Apollo Hospitals Enterprise Limited reported results for the quarter ended June 30, 2026 (Q1 FY2026-27), with revenue reaching ₹7,043.5 crore, crossing the ₹7,000 crore threshold for the first time. Revenue rose 20.6% from the same quarter last year, while profit before tax grew 38.0% to ₹785.4 crore. Both PBT margin and net profit margin expanded, and the quarter continued a pattern of sequential revenue increases.
Profit before tax (PBT) rose 38.0% year-on-year to ₹785.4 crore, and net profit grew 38.4% to ₹610.4 crore. Both growth rates outpaced the 20.6% revenue increase, indicating an improvement in overall profitability.
| Metric | Q1 FY2025-26 | Q1 FY2026-27 | Change |
|---|---|---|---|
| Revenue (₹ Cr) | 5,842.1 | 7,043.5 | +20.6% |
| PBT (₹ Cr) | 569.1 | 785.4 | +38.0% |
| Net Profit (₹ Cr) | 441.0 | 610.4 | +38.4% |
| PBT Margin | 9.74% | 11.15% | +1.41 pp |
| Net Profit Margin | 7.55% | 8.67% | +1.12 pp |
The margin expansion occurred even as one major cost line—other expenses—grew faster than revenue.
Apollo Hospitals reported strong Q1FY27 results with consolidated revenue up 21% YoY to ₹7,043 Cr and EBITDA up 28% YoY to ₹1,092 Cr. Management attributed growth to robust volume increases in high-complexity specialties, strong occupancy (70% vs 65% YoY), and steady international patient demand (26% YoY growth). The company continues to expand capacity with plans to add over 5,800 beds over the next five years, including the recent launch of a 180-bed hospital in Sarjapur and upcoming facilities in Gurugram, Indore, and Ranchi. Apollo HealthCo reported 20% revenue growth, driven by its omni-channel pharmacy network (7,440 stores) and digital platform Apollo 24/7.
Management emphasized a strategic shift towards preventive and patient-centric care, leveraging the integrated healthcare ecosystem to address the rising burden of non-communicable diseases. Key risks include ongoing legal proceedings against a subsidiary regarding land allotment in Karnataka, though an interim stay has been granted, and initial EBITDA losses of ₹38 Cr from new hospitals. Overall, management remains focused on disciplined expansion, prudent capital allocation, and clinical excellence.
Category: B2B Services
Owns and operates multi-specialty tertiary and quaternary care hospitals specializing in cardiology, oncology, organ transplants, and orthopedics.
Key Products & Services: Apollo Hospitals
Category: Consumer Tech
Manages the retail pharmacy chain, online pharmacy sales, diagnostics bookings, and teleconsultations through Apollo 24/7.
Key Products & Services: Apollo 24/7 • Apollo Pharmacy
Category: B2B Services
Operates primary care clinics (Apollo Clinic), diagnostic laboratories (Apollo Diagnostics), day-surgery units (Apollo Spectra), and cradle care hospitals.
Key Products & Services: Apollo Health and Lifestyle Limited (AHLL) • Apollo Clinic • Apollo Diagnostics • Apollo Spectra
Core Thesis: An omnichannel healthcare model linking physical clinical assets, wholesale pharmaceutical supply chains, and digital patient services.
• Omnichannel Healthcare (Apollo 24/7): The digital platform integrates teleconsultations, laboratory bookings, and prescription delivery, connecting customer data to EHR systems. • Keimed Supply Chain Integration: Keimed acts as the central procurement partner, managing logistics and supplying stock to Apollo's retail pharmacies, hospital dispensaries, and digital hubs. • Clinical Referral Funnel (AHLL): AHLL centers serve as low-cost patient entry points, referring patients requiring advanced care to Apollo's primary multi-specialty hospitals. • Digital Inventory Integration: Centralized ERP systems coordinate drug inventory across physical stores and online distribution centers for efficient last-mile delivery.